Summary by Futu AI
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, has filed a Post-Effective Amendment No. 1 to Form F-1 with the SEC on May 2, 2024. The amendment relates to the Registration Statement on Form F-1, originally declared effective by the SEC on March 6, 2024, under Registration No. 333-277394. The filing is part of SciSparc's undertaking to update and supplement information contained in the Registration Statement concerning the offer and sale of up to 5,402,887 ordinary shares by YA II PN, LTD., a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP. The filing updates and supplements the Registration Statement and the prospectus contained therein, with no additional securities being registered under this amendment. The prospectus is not complete and may be changed...Show More